The phase Ib study evaluated nivolumab (3 mg/kg every 2 weeks) in combination with ceritinib (n = 14: 450 mg/day or n = 22: 300 mg/day) in 36 patients with previously treated or untreated stage IIIB/IV ALK-rearranged NSCLC [60]. Here, ALK is linked to non-small cell lung carcinoma.